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Background: Understanding the effects of cancer on the quality of life of affected patients is critical to clinical
research as well as to optimal management and care. The aim of this study was to adapt the European Organization
for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) questionnaire into Moroccan
Arabic and to determine its psychometric properties. After translation, back translation and pretesting of the
pre-final version, the translated version was submitted to a committee of professionals composed by oncologists
and epidemiologists. The psychometric properties were tested in patients with cancer. Internal consistency was
tested using Cronbach’s alpha and the test-retest reliability using interclass correlation coefficients. Construct
validity was assessed by examining item-convergent and divergent validity. It was also tested using Spearman’s
correlation between QLQ-C30 scales and EQ-5D.
Results: The study was conducted in 125 patients. The Moroccan version was internally reliable, Cronbach’s α
was 0.87 for the total scale and ranged from 0.34 to 0.97 for the subscales. The intraclass correlation coefficient
of the test-retest reliability ranged from 0.64 for “social functioning” to 0.89 for “physical activities” subscales. The
instrument demonstrated a good construct and concomitant validity.
Conclusions: We have developed a semantically equivalent translation with cultural adaptation of EORTC
QLQ-C30 questionnaire. The assessment of its measurement properties showed that it is quite reliable and a
valid measure of the effect of cancer on the quality of life in Moroccan patients.
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Understanding the effects of cancer on the quality of life
of affected patients is critical to clinical research as well
as to optimal management and care. Measurement of
quality of life is helpful in guiding management decisions.
Furthermore, it is useful to monitor the effect of therapy
on patients’ quality of life. The use of quality of life
measures is usually welcomed by patients who wish to
express their concerns.* Correspondence: elfakirsamira@yahoo.fr
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reproduction in any medium, provided the orPatients with cancer, enter therapy with the recogni-
tion that therapy aimed to cure is often accompanied
by side effects that have a negative impact on their
quality of life [1]. In recent years, many clinical cancer
treatment research protocols have included a quality of
life feature to evaluate the balance between side effects
and quality of life during sometimes highly toxic treatment
regimens [2,3].
Quality of life addresses not only functional abilities,
but also symptoms, side effects, and other issues such as
social, psychological, spiritual, family, and financial as-
pects. The assessment of quality of life is becoming a
standard component in the overall care of patients withLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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an additional outcome measure in the comparisons of
different oncological treatment regimens.
In Morocco, there is no experience with patient-reported
measurements of health-related quality of life in cancer
patients. The availability of valid and reliable Moroccan
version of quality of life instruments is critical to collect
such measurement. Any tool designed to measure quality
of life should be multidimensional, subjective, useful in
setting, valid, and reliable.
One of the most popular instruments used with cancer
patients is the EORTC QLQ-C30 [4].
Culturally adapting an existing instrument rather than
composing a new one has several advantages. The cost
and time-consuming process of developing a new test is
avoided, and the use of standard measure permits cross-
cultural comparisons [5].
Cross-cultural adaptation of a quality of life instrument
is a step-wise process [5,6].
This incremental methodological approach has become
even more essential as increasing experiences have accu-
mulated about cultural differences in the measurement of
quality of life, and the recognition of different type of
“equivalence” between cultures [7]. However, most adapta-
tion process consists of two primary steps: assessment of
the equivalence between the source instrument and the
instrument being adapted, and evaluation of the measure-
ment properties of the adapted instrument.
The aims of the current study were to translate into
Moroccan Arabic and culturally adapt the EORTC
QLQ-C30 (version 3.0), and to assess the psychometric
properties of this translation.
Methods
Translation and cultural adaptation of the EORTC QLQ-C30
The EORTC QLQ-C30 is a 30-item questionnaire com-
posed of nine multi-item scales and six single items. We
followed the published guidelines for cross-cultural adap-
tation of health-related quality of life measurements [5,8].
As only well-educated Moroccans have a good command
of the official language in Morocco, Standard-Arabic,
we translated the questionnaire into the oral language
commonly spoken among Moroccan people: Moroccan
Arabic. Some words could not be translated literally
into Moroccan-Arabic, so they were replaced with a short
description. For example, there are no Moroccan-Arabic
equivalents for the words ‘Hobby’ or ‘quality’. In these
cases a Standard-Arabic word was used in addition to the
short description.
Patient recruitment
Between October and November 2009, cancer patients
were recruited from the two main oncology centers in
the country (National institute of oncology in Rabat andoncology center of Ibn Rochd hospital in Casablanca).
Patients attending these two centers are from around
the country (north, center and south). The sample size
was defined according to Streiner curve [9] for an ICC
of 0.70 and a precision of ± 0.10. Patients were eligible if
they were at least 18 years old, had a confirmed diagnosis
of cancer and spoke Moroccan Arabic. Ethical approval
was obtained from the ethics committees in the University
Hospital Center Hassan II in Fez- Morocco and all the
subjects were informed of the conditions related to the
study and gave their written, informed consent.
Instruments and procedures
The Arabic version of the EORTC QLQ-C30 were admin-
istered to patients by two different interviewers. The order
of interviewers was randomly defined.
The same questionnaire was re- administered three to
ten days later to assess reproducibility.
All participants were also asked to fill in the Euroquol
5 Dimension (EQ-5D) questionnaire which is a standard-
ized instrument to measure health outcome. It provides a
simple descriptive profile and a single index value of
health status ranging from 0 (death) to 1 (perfect health).
EQ-5D consists of five questions covering the dimensions
of mobility, self-care, usual activities, pain/discomfort and
anxiety/depression, each with three levels of response.
The psychometric properties of the Moroccan version
were adequate. The Kappa coefficient ranged from 0.49 to
0.92, the intraclass correlation coefficient (ICC) was 0.92
and good correlations between EQ-5D and SF-36 dimen-
sions were noted (r = 0.53 to 0.85) [10].
Participants provided socio-demographic and clinical
data and a measure of pain on a visual analogical scale
(VAS).
Statistical analysis
Scores on the items and scales were linearly transformed
to a scale from 0 to 100. A high score for a functional
scale represents a healthy level of functioning, a high
score for the global health status represents a high quality
of life, but a high score for a symptom scale/item repre-
sents a high level of symptomatology [11].
Descriptive statistics were generated to evaluate missing
data and score distributions (i.e. mean, range, floor and
ceiling effects).
Internal consistency reliability of the multi-item scales
was assessed by Cronbach’s coefficient α. A value of 0.70
or greater was considered as adequate [12]. Inter-rater
and test-retest reliabilities were assessed by the intraclass
correlation coefficient (ICC), derived from a two-way
analysis of variance in a random effect model.
Multitrait scaling analysis were employed to examine
item-convergent validity (item-scale correlations should
be >0.40) and item-discriminant validity (items should
































Cervical cancer 10 (8.0)
Colorectal 10 (8.0)
Stomach 4 (3.2)
Age mean (SD) 44.2 (16.0)
EQ-5D mean (SD) 0.49 (0.35)
Third assessment (test-retest) 85 (68.0)
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other scales). Construct validity was also tested using
Spearman’s correlation between QLQ-C30 scales and
EQ-5D.
All statistical analyses were performed using SPSS 17.0.
Results
Sample socio-demographic and clinical characteristics
125 patients participated in the study, 65 were re-
cruited in Rabat and 60 in Casablanca. Sociodemo-
graphic and clinical characteristics of the study sample
are shown in Table 1. Participants ranged in age from
19 to 81 years; the mean age was 44 years (SD: 16). 54%
were males and 57% were illiterate. The most common
primary cancer diagnoses were cancer of lung (17%),
breast (16%) and cavum (9%). 67 patients underwent
the third assessment.
Acceptability
The average time to complete the QLQ-C30 was 10 min.
On average, missing data rate for items was 1.1% (range
0–1.6%). The items that had missing responses were
item 4 of “Physical functioning” scale, items 6 and 7 of
“Role functioning”, item 8 “dyspnoea”, items 18 and 19
of “fatigue” and “pain” and item 30 of “global health
status”.
Descriptive statistics
Scores distributions are shown in Table 2. The scores for
different scales ranged from 43.4 to 88.7. “Role functioning”
scale had the lower score (median 33.3), “social function-
ing” scale had a median score at 100. Financial difficulties
were common with a median at 100. The most frequent
symptoms were nausea and vomiting, appetite loss and
pain.
High ceiling or floor effects were observed for the “Role
functioning”, “cognitive functioning” and “social function-
ing” scales and for most of the single item symptom scales
(Table 2).
Reliability
Cronbach’s α was 0.87 for the total scale and ranged
from 0.34 for “cognitive functioning” to 0.94 for “role
functioning”, indicating good internal consistency (Table 3).
Inter-ratter reliability was substantial for the nine scales
and the independent items (Table 3).
Test-retest reliability was assessed using the intraclass
correlation coefficient, which ranged from 0.64 for “social
functioning” to 0.89 for “physical activities”.
Construct validity
All items exceeded the 0.4 criterion for convergent validity
in all scales (Table 4).Item-discriminant validity was 100% successful for all
items except item 10, 12 and 18. “Fatigue” items were
highly correlated with “Physical functioning” scale and
item 10 was highly correlated with “global health status”.
The EQ-5D was highly correlated with “Physical
functioning” and “Emotional functioning”, and moderately
correlated with “Role functioning”, “Global health status”
and “Fatigue”. VAS pain was moderately correlated with
“pain” scale (Table 5).
Table 2 Subscale scores and floor and ceiling effect
N Median Mean Standard deviation Floor effecta (%) Ceiling effectb (%)
Physical functioning 125 60.00 53.86 31.76 7.9 10.3
Role functioning 125 33.33 43.41 43.9 42.1 30.2
Emotional functioning 124 66.67 64.07 33.00 9.5 27.0
cognitive functioning 125 66.67 68.80 31.11 4.8 38.1
Social functioning 125 100 88.67 24.10 3.2 73.8
Global health status 125 50.00 53.25 30.31 7.1 11.9
Fatigue 125 44.44 45.56 33.15 19.0 11.1
Nausea and vomiting 125 66.67 64.13 35.67 11.1 36.5
Pain 125 66.67 60.27 38.03 16.7 33.3
Dyspnoea 124 0.00 27.15 35.65 57.1 9.5
Insomnia 125 0.00 33.86 42.33 57.9 20.6
Appetite loss 125 66.67 61.33 41.35 24.6 44.4
Constipation 125 0.00 26.93 38.73 62.7 15.1
Diarrhoea 125 0.00 18.40 30.95 68.3 6.3
Financial difficulties 125 100 77.33 36.32 13.5 65.9
apercentage of the lowest modality.
bpercentage of the highest modality.
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In this paper, we report the result of a cross-cultural
adaptation and evaluation of the psychometric properties
of the Moroccan Arabic version of the EORTC QLQ-C30.
This instrument has been developed in 1987 by the
European Organisation for Research and Treatment of
Cancer. The EORTC QLQ-C30 has been internationally
validated [13-17], and is currently available in more thanTable 3 Internal consistency and reliability of the EORTC
QLQ-C30
Cronbach’s α Reliability ICC (IC 95%)
Inter-ratter Test-retest
Physical functioning 0.84 0.92 [0.88-0.94] 0.89 [0.85-0.93]
Role functioning 0.94 0.82 [0.75-0.87] 0.80 [0.71-0.87]
Emotional functioning 0.89 0.82 [0.76-0.87] 0.82 [0.74-0.88]
cognitive functioning 0.34 0.83 [0.77-0.88] 0.72 [0.61-0.81]
Social functioning 0.80 0.78 [0.69-0.84] 0.64 [0.50-0.75]
Global health status 0.87 0.84 [0.78-0.89] 0.76 [0.66-0.84]
Fatigue 0.83 0.82 [0.75-0.87] 0.84 [0.76-0.89]
Nausea and vomiting 0.74 0.83 [0.77-0.88] 0.78 [0.67-0.85]
Pain 0.78 0.90 [0.86-0.93] 0.82 [0.74-0.88]
Dyspnoea - 0.78 [0.68-0.84] 0.78 [0.68-0.85]
Insomnia - 0.73 [0.63-0.81] 0.74 [0.62-0.82]
Appetite loss - 0.83 [0.77-0.88] 0.75 [0.65-0.83]
Constipation - 0.89 [0.85-0.92] 0.82 [0.73-0.88]
Diarrhoea - 0.78 [0.70-0.84] 0.75 [0.64-0.83]
Financial difficulties - 0.74 [0.65-0.81] 0.80 [0.71-0.87]81 languages (www.eortc.be). It was validated to use
among Moroccan ethnic minority cancer patients in
the Netherlands [18]. However the majority of Moroccan
immigrants living in Netherlands were from rural areas of
north Morocco where the most common oral language is
“Tarifit” and where the educational and literacy levels are
lower than national standards. To our knowledge, it is the
first Moroccan Arabic validation of a cancer quality of life
instrument. This new validated scale will provide informa-
tion on the functional health and well-being of Moroccan
patients in order to provide them with optimal health care
services.
To obtain this scale, we followed the international
guidelines for cross-cultural adaptation of health-related
quality of life measures [5,8].
The average time required to complete the question-
naire was similar to that reported in earlier studies
[4,15,17,18].
Time between test and retest was three days on aver-
age. Streiner and Norman indicate that expert opinions
regarding the appropriate interval vary from one hour to
one year, depending on the task, but generally, a retest
interval of 2 to 14 days is usually used [19].
The reliability and validity of the Moroccan Arabic
version of the EORTC QLQ-C30 were satisfactory. The
hypothesized scale structure of the questionnaire was
largely confirmed. Cronbach’s alpha coefficient was high
for all scales except “cognitive functioning”, indicating
adequate internal reliability. Problems with the psycho-
metric properties of “cognitive functioning” scale have
been reported in other studies [4,18]. Inter-ratter and
Table 4 Multitrait scaling analysis of the EORTC QLQ-C30 questionnaire (Moroccan Arabic Version)






Physical functioning 0.72-0.86 5/5 40/40
Role functioning 0.98-0.98 2/2 16/16
Emotional functioning 0.85-0.89 4/4 32/32
cognitive functioning 0.73-0.82 2/2 16/16
Social functioning 0.89-0.92 2/2 16/16
Global health status 0.94-0.94 2/2 16/16
Fatigue 0.81-0.89 3/3 20/24
Nausea and vomiting 0.89-0.90 2/2 16/16
Pain 0.90-0.93 2/2 16/16
aNumber of item-scale correlations greater than 0.40/total number of item-scale correlations.
bnumber of correlations of items with own scales significantly higher than correlations with other scale/total number of correlations.
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subscales, ICC inter-ratter ranged from 0.73 to 0.92 and
test-retest from 0.64 to 0.89.
Construct validity was assessed by testing convergent
and discriminant validity of the items, and the associations
between the scores of each domain and the EQ-5D score.
The most common concurrent scale used in validation
studies was the SF36. We could not use this scale because
it included 36 items, it could be hard for patients to
complete the EORTC QLQ-C30 questionnaire twice and
the SF36. The EQ-5D which is a short scale was preferred,
especially since administration of the questionnaire need
more time than auto-administration.
All items exceeded the 0.4 criterion for convergent
validity on all scales. Item-discriminant validity was
100% successful for all items except three. “Fatigue”
items were highly correlated with “physical functioning”
scale, this result was also observed in the validation study
among the Moroccan group living in Netherlands [18].
VAS pain was not highly correlated with “pain” scale
because the EORTC QLQ-C30 pain scale measures pain
during the past week and VAS pain gives an instantaneous
measure during the interview.
Known group’s validity was not tested because the
number of missing data about disease stage and treatment
status was high.
Because of the high level of illiteracy, an interviewer
had administered the questionnaire for all patients. Unlike
northern countries, the questionnaire could not be usedTable 5 Correlations between EORTC QLQ-C30 scales,
EQ-5D and VAS pain
EORTC QLQ-C30
PF RF EF CF SF GHS FA NV PA
EQ-5D 0.66 0.50 0.43 0.44 0.22 −0.41 0.55 0.27 0.62
VAS pain −0.25 −0.32 −0.25 −0.32 −0.06 0.27 −0.28 −0.16 −0.59as an auto-administered questionnaire except for a minority
of Moroccan population.
One of the limitations of this study is that responsive-
ness over time is not performed. We would recommend
that additional studies be carried out with patients under
active treatment in order to document the responsiveness.
Despite the fact that Arabic language is commonly
spoken across the country, there are some other regional
languages such as “Tarifit”, “Tamazight” and “Tachelhit”.
But, the majority of these people speak also Arabic. Fur-
ther validation should be specifically performed in these
regions because inclusion of these patient groups in local
or national clinical studies is essential.
Conclusion
We conclude that the Moroccan Arabic version of the
EORTC QLQ-C30 is a reliable and valid measure of the
quality of life in cancer patients and can be used in co-
hort studies. However, confirmation of its responsiveness
requires a formal study assessing the effect of a specific
therapeutic intervention.
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